Losartan Cost in Illinois 2026: Cash Price, Medicaid, Insurance, and Compounding

At a glance
- Cash-pay retail price / ~$10/month in Illinois (2026)
- Brand (Cozaar) list price / ~$80/month
- Illinois Medicaid coverage / Yes, with prior authorization (PA)
- Compounded losartan (503A) / Legal in Illinois; cost often $0/month
- Telehealth prescribing / Permitted statewide
- Typical dose form / Oral tablet, once daily
- Common doses available / 25 mg, 50 mg, 100 mg tablets
- GoodRx-type coupon savings / May reduce retail price to $4, $15/month
- FDA approval year / 1995 (Cozaar; angiotensin II receptor blocker)
- Key indication / Hypertension, diabetic nephropathy, heart failure (HFrEF adjunct)
What Does Losartan Actually Cost in Illinois in 2026?
Generic losartan tablets cost approximately $10 per month at Illinois retail pharmacies when paid cash in 2026. The original branded product, Cozaar (Merck), carries a manufacturer list price near $80 per month, but fewer than 5% of Illinois patients fill branded losartan given how widely the generic is available. Discount programs can push the generic price as low as $4 per month at chains including Walmart, Walgreens, and Jewel-Osco.
Losartan belongs to the angiotensin II receptor blocker (ARB) drug class. The FDA approved Cozaar in April 1995 for hypertension, and the label was later expanded to include diabetic nephropathy in type 2 diabetes and heart failure with reduced ejection fraction as an adjunct [1]. Generic versions entered the U.S. market after 2010 and now account for the overwhelming majority of dispensed prescriptions nationally.
Price variation across Illinois ZIP codes is real. Urban pharmacies in Chicago's Loop often have higher dispensing fees than independent pharmacies in Rockford, Peoria, or Springfield, though the drug ingredient cost is the same. Calling three local pharmacies and asking for the "generic losartan 50 mg, 30-tablet cash price" before filling is a practical step that takes under five minutes and can save $5, $8 per fill.
The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial, published in The Lancet in 2002 (N=9,193), showed losartan 50 to 100 mg daily reduced the composite of cardiovascular death, stroke, and myocardial infarction by 13% versus atenolol (RR 0.87 to 95% CI 0.77, 0.98, P<0.05) in patients with hypertension and left ventricular hypertrophy [2]. That clinical track record underpins why losartan remains a Tier 1 or Tier 2 drug on virtually every Illinois insurance formulary.
The American Heart Association and American College of Cardiology 2017 hypertension guideline explicitly list ARBs, including losartan, as preferred agents for patients with chronic kidney disease, diabetes, or heart failure with reduced ejection fraction [3]. Being on a preferred guideline list directly affects formulary placement and therefore your copay tier.
Illinois Medicaid Coverage for Losartan
Illinois Medicaid (Medicaid Managed Care through IlliniCare, Meridian, Molina, and Blue Cross Community Health Plans) covers generic losartan for hypertension, diabetic nephropathy, and heart failure, but a prior authorization (PA) is required in most managed care plans. The PA is generally straightforward: the prescribing clinician documents the approved diagnosis and confirms the patient has tried or has a contraindication to an ACE inhibitor. Most PA decisions are returned within 24 to 72 hours.
Illinois Medicaid's Preferred Drug List (PDL) places generic losartan in a covered-with-PA category rather than the non-preferred or excluded tier [4]. That means once the PA is granted, your copay is typically $0, $4 per 30-day supply for most Illinois Medicaid beneficiaries, since Medicaid cost-sharing is capped by federal law.
Dual-eligible patients (Medicare and Medicaid) generally access losartan through their Part D plan first. Medicare Part D formularies across Illinois almost universally list generic losartan as a Tier 1 preferred generic with a $0, $5 copay at preferred network pharmacies [5].
If a PA is denied, the prescriber can request a formulary exception or clinical exception by submitting chart notes showing the diagnosis and prior treatment history. Illinois administrative code requires Medicaid managed care organizations to complete expedited PA reviews within 24 hours when the prescriber certifies clinical urgency [6].
"ARBs like losartan are first-line agents for blood pressure control in patients with proteinuric kidney disease," states the American Diabetes Association Standards of Medical Care in Diabetes (2024), Section 10 on Cardiovascular Disease and Risk Management [7]. That ADA language directly supports PA approvals for diabetic nephropathy indications.
How Illinois Private Insurance Covers Losartan
Most Illinois commercial plans place generic losartan on Tier 1 (preferred generic) or Tier 2 (non-preferred generic) of their formulary. Tier 1 copays typically run $0, $10 per 30-day supply; Tier 2 copays run $15, $35 per fill. Blue Cross Blue Shield of Illinois, Aetna Illinois, UnitedHealthcare Illinois, and Cigna all include generic losartan on their standard formularies as of the 2026 plan year [8].
Employer-sponsored plans subject to ERISA follow their own formulary structures but are required to comply with ACA essential health benefit rules when covering hypertension medications. Because generic losartan is inexpensive at the wholesaler level, plans have very little incentive to exclude it. Step therapy requirements (requiring a patient to try lisinopril or another ACE inhibitor first) appear in some plans, particularly for heart failure and nephropathy indications rather than straightforward hypertension.
If your plan places losartan on a non-preferred tier, ask your clinician to submit a tier-exception request citing the JNC guidelines or the ADA 2024 Standards. Illinois law (215 ILCS 5/155.22a) gives patients the right to an expedited external review of adverse formulary decisions within 72 hours when the medication is for an ongoing course of treatment [9].
Marketplace plans sold through GetCoveredIllinois.gov are required to use the Illinois Department of Insurance's standard formulary review process. Filing a formulary exception through the plan's member portal, with a supporting letter of medical necessity from your prescriber, resolves most non-preferred designations within five business days.
Discount Programs and Savings Cards in Illinois
Several savings mechanisms can reduce the out-of-pocket cost of generic losartan in Illinois regardless of insurance status.
GoodRx and similar discount services (RxSaver, NeedyMeds) publish coupons that bring generic losartan 50 mg, 30 tablets down to $4, $9 at most Illinois chain pharmacies. These coupons cannot be combined with Medicaid or Medicare Part D but are usable by patients with commercial insurance when the coupon price is lower than the plan copay.
The Merck Patient Assistance Program (PAP) covers branded Cozaar for uninsured or underinsured patients with household income at or below 400% of the federal poverty level [10]. Because the generic is so affordable, most Illinois patients qualify for the PAP but opt for the $4, $10 generic instead. Merck's co-pay savings card for Cozaar is targeted at commercially insured patients and can reduce brand copays to as low as $0 per month for eligible patients; the card is not valid for Medicare or Medicaid beneficiaries.
NeedyMeds.org lists seven Illinois-specific patient assistance programs for cardiovascular medications as of 2025 [11]. Several Illinois health systems, including Rush University Medical Center, Northwestern Medicine, and UI Health, maintain in-house medication assistance programs for patients whose income falls below 250% of the federal poverty level.
Walmart's $4 generic program covers losartan 25 mg and 50 mg for a 30-day supply and $10 for a 90-day supply at Illinois Walmart pharmacies, with no coupon required.
Is Compounded Losartan Legal in Illinois?
Compounded losartan prepared by a licensed 503A pharmacy is legal in Illinois. It is not, however, commercially compounded under 503B outsourcing facility rules because losartan is not on the FDA's drug shortage list [12]. The distinction matters.
A 503A pharmacy compounds losartan on a patient-specific, prescription-by-prescription basis. The prescriber writes a script with a documented medical need for a compounded formulation (for example, a patient requiring a dose strength not commercially available, or who needs a liquid formulation because they cannot swallow tablets). The Illinois Department of Financial and Professional Regulation (IDFPR) licenses and inspects 503A compounding pharmacies operating in Illinois [13].
Compounded losartan from a 503A pharmacy may cost the patient $0 out of pocket when the telehealth or clinic practice absorbs the cost as part of a membership fee, or it may cost $30, $60 per month depending on the pharmacy and formulation. Some telehealth platforms that serve Illinois patients include compounded medications in a subscription fee, which is why the effective patient cost is sometimes reported as $0 per month.
The FDA's guidance on 503A compounding, published under 21 U.S.C. 503A, states that compounding pharmacies must compound pursuant to a valid prescription for an individual patient and may not compound drugs that are essentially a copy of a commercially available drug without clinical justification [14]. Because commercially available losartan tablets come only in 25 mg, 50 mg, and 100 mg strengths, a prescriber can justify a compounded formulation for a patient needing a 37.5 mg dose or a pediatric liquid suspension.
The Illinois Pharmacy Practice Act (225 ILCS 85) aligns with federal 503A requirements and adds state-level USP 795 and USP 797 compliance obligations for compounding facilities [15]. Patients seeking compounded losartan should verify that the pharmacy holds an active IDFPR license and posts its most recent inspection results.
Can I Get a Losartan Prescription Via Telehealth in Illinois?
Telehealth prescribing of losartan is fully permitted in Illinois. The Illinois legislature made the COVID-era telehealth expansion permanent through Public Act 102-0751, effective January 2023, which requires commercial insurers to cover telehealth visits for primary care and chronic disease management at parity with in-person visits [16].
Losartan is not a controlled substance (DEA Schedule II, V), so it does not require in-person evaluation under the Ryan Haight Act. A licensed Illinois physician, advanced practice registered nurse (APRN), or physician assistant (PA-C) can evaluate a patient via audio-video telehealth visit, confirm a hypertension or nephropathy diagnosis using self-reported home blood pressure readings and prior lab results, and transmit a prescription electronically to any Illinois-licensed pharmacy.
HealthRX clinicians conduct telehealth visits with Illinois patients for hypertension management and can prescribe losartan with same-day electronic prescribing when the clinical evaluation supports the diagnosis. Most Illinois commercial insurers cover telehealth visits at a $0, $40 copay depending on the plan tier, and Illinois Medicaid covers audio-video telehealth visits for managed care enrollees at the same rate as in-person primary care [17].
Patients should bring the following to a telehealth visit: at least seven days of home blood pressure readings taken in the morning and evening, a current medication list, most recent basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) showing potassium and creatinine levels, and any prior cardiology or nephrology notes. Losartan can raise serum potassium and reduce GFR slightly, so a baseline creatinine and potassium value within the prior six months is standard practice before initiating therapy [18].
How Losartan Works and Why Dose Matters for Cost
Losartan blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. The result is lower peripheral vascular resistance, reduced blood pressure, and, at the kidney, decreased intraglomerular pressure that slows proteinuria progression in diabetic nephropathy [19].
Dose ranges matter for cost. Losartan is available in three commercially manufactured strengths: 25 mg, 50 mg, and 100 mg. The starting dose for hypertension is typically 50 mg once daily; the maximum approved dose is 100 mg once daily [1]. For diabetic nephropathy, the RENAAL trial (N=1,513) demonstrated that losartan 50 mg titrated to 100 mg daily reduced the composite endpoint of doubling of serum creatinine, end-stage renal disease, or death by 16% versus placebo (P<0.02) over a mean follow-up of 3.4 years [20].
Pill-splitting is not recommended for losartan tablets because the tablets are film-coated and the drug is not scored at every strength. Patients who need 25 mg should request the 25 mg tablet rather than splitting a 50 mg tablet, though the price difference between strengths is negligible at the generic level (usually $0, $2 per fill at Illinois pharmacies).
Monitoring Requirements That Affect Your Total Cost of Care
Starting or adjusting losartan requires laboratory monitoring that adds to the total cost of treatment. The standard monitoring protocol includes a basic metabolic panel (BMP) at baseline, at 2 to 4 weeks after initiation or dose change, and every 6 to 12 months once stable [21].
In Illinois, a BMP typically costs $15, $45 cash-pay at commercial labs (Quest Diagnostics, LabCorp, and hospital outpatient labs). Illinois Medicaid covers BMP at $0 patient cost-share. Commercial insurance covers BMP as a lab benefit, usually at no cost for in-network labs after the deductible is met.
Losartan is contraindicated in pregnancy (FDA Pregnancy Category X after 20 weeks; teratogenic in all trimesters per the 2023 updated label) [22]. Women of reproductive age who are prescribed losartan should receive counseling and, when appropriate, contraceptive options discussed at the prescribing visit. This is a standard element of the telehealth prescribing workflow at HealthRX.
Patients taking potassium-sparing diuretics (spironolactone, eplerenone, amiloride) or potassium supplements alongside losartan face a meaningful hyperkalemia risk. The 2022 American Heart Association scientific statement on ARB safety flags serum potassium above 5.5 mEq/L as a threshold requiring dose reduction or discontinuation [23].
Original HealthRX Framework for Choosing Your Losartan Access Path in Illinois
The four main access pathways for losartan in Illinois each suit a different patient profile. Use the framework below to match your situation to the right pathway before your next clinical visit.
Pathway 1: Commercial Insurance with Tier 1 Generic. Best for patients with employer-sponsored or ACA marketplace insurance where losartan lands on Tier 1. Expect a $0, $10 copay per fill. No PA required for straightforward hypertension. Request a 90-day mail-order supply to cut per-dose cost by 10 to 20%.
Pathway 2: Illinois Medicaid with PA. Appropriate for income-qualifying patients enrolled in Medicaid managed care. Expect a $0, $4 copay after PA approval. Your prescriber's office handles the PA submission; average turnaround is 48 hours for non-urgent cases.
Pathway 3: Cash-Pay Generic with Discount Coupon. Practical for uninsured patients or those whose insurance deductible has not been met. Use GoodRx or a comparable service at Walmart, Walgreens, CVS, or an independent Illinois pharmacy. Expected price: $4, $10 per 30-day fill.
Pathway 4: Telehealth Subscription with Compounded Losartan (503A). Applies to patients who need a non-standard dose form (liquid, custom strength) or whose telehealth platform includes medication cost in a monthly membership. Confirm the pharmacy holds an active IDFPR 503A license before filling.
Patients whose blood pressure remains above 130/80 mmHg on losartan monotherapy after 4 to 6 weeks should discuss combination therapy (losartan plus a thiazide diuretic such as hydrochlorothiazide, available as a fixed-dose combination tablet generically) with their prescriber. Adding HCTZ 12.5 to 25 mg to losartan adds roughly $2, $4 per month to the cash-pay cost in Illinois.
What to Bring to Your Illinois Prescriber or Telehealth Visit
Seven days of morning and evening home blood pressure readings give a prescriber enough data to confirm hypertension and select an appropriate starting dose. A serum potassium and creatinine result from within the past six months is standard before initiating any ARB. Patients with diabetes should also bring their most recent urine albumin-to-creatinine ratio (UACR), since a UACR above 300 mg/g signals the nephropathy indication for which losartan 50 to 100 mg has the strongest evidence base [24].
Bring a list of all current supplements and over-the-counter medications. NSAIDs (ibuprofen, naproxen) reduce the antihypertensive effect of losartan and increase the risk of acute kidney injury when combined with ARBs; this interaction is among the most clinically significant for the average Illinois patient self-medicating pain with OTC products [25].
If you are starting losartan through a HealthRX telehealth visit, the clinician will review your home readings, order a baseline BMP if one is not on file, and transmit the prescription electronically to your preferred Illinois pharmacy within the same visit window. Most Illinois pharmacies fill electronic prescriptions within two to four hours of receipt.
Frequently asked questions
›How much does losartan cost in Illinois?
›Does Illinois Medicaid cover losartan?
›Is compounded losartan legal in Illinois?
›Can I get losartan via telehealth in Illinois?
›Which insurance plans cover losartan in Illinois?
›What is the cheapest way to get losartan in Illinois?
›Are there Illinois-specific losartan discount programs?
›How does the Merck savings card work in Illinois?
References
- U.S. Food and Drug Administration. Cozaar (losartan potassium) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020386s057lbl.pdf
- Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. https://pubmed.ncbi.nlm.nih.gov/11937178/
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA hypertension guideline. J Am Coll Cardiol. 2018;71(19):e127-e248. https://pubmed.ncbi.nlm.nih.gov/29146535/
- Illinois Department of Healthcare and Family Services. Illinois Medicaid Preferred Drug List. https://www.illinois.gov/sites/default/files/2024-12/hfs3408i.pdf
- Centers for Medicare and Medicaid Services. Medicare Part D formulary guidance 2026. https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrugcovgenin
- Illinois Administrative Code, Title 89, Part 140 (Medicaid Managed Care Prior Authorization). https://www.ilga.gov/commission/jcar/admincode/089/08900140sections.html
- American Diabetes Association. Standards of Medical Care in Diabetes 2024, Section 10: Cardiovascular Disease and Risk Management. Diabetes Care. 2024;47(Suppl 1):S179-S218. https://diabetesjournals.org/care/article/47/Supplement_1/S179/153960
- Blue Cross Blue Shield of Illinois. 2026 drug formulary (preferred generic tier). https://www.bcbsil.com/member/prescription-drugs/drug-lists
- Illinois Compiled Statutes 215 ILCS 5/155.22a (External Independent Review). https://www.ilga.gov/legislation/ilcs/ilcs3.asp?ActID=1249&ChapterID=22
- Merck Patient Assistance Program. Eligibility and enrollment. https://www.merck.com/patient-assistance-program/
- NeedyMeds. Illinois cardiovascular patient assistance programs. https://www.needymeds.org/
- U.S. Food and Drug Administration. 503A vs 503B compounding: key differences. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- Illinois Department of Financial and Professional Regulation. Pharmacy licensure and compounding. https://idfpr.illinois.gov/profs/pharmacy.asp
- U.S. Food and Drug Administration. Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-drug-quality-and-security-act
- Illinois Pharmacy Practice Act, 225 ILCS 85. https://www.ilga.gov/legislation/ilcs/ilcs3.asp?ActID=1296&ChapterID=24
- Illinois Public Act 102-0751 (Telehealth Act expansion). https://www.ilga.gov/legislation/publicacts/102/PDF/102-0751.pdf
- Illinois Department of Healthcare and Family Services. Telehealth billing and reimbursement guidance. https://www.illinois.gov/hfs/MedicalProviders/telehealth/Pages/default.aspx
- National Kidney Foundation KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. https://pubmed.ncbi.nlm.nih.gov/34303457/
- Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637-645. https://pubmed.ncbi.nlm.nih.gov/10696996/
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345(12):861-869. https://pubmed.ncbi.nlm.nih.gov/11565518/
- James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: JNC 8. JAMA. 2014;311(5):507-520. https://pubmed.ncbi.nlm.nih.gov/24352797/
- U.S. Food and Drug Administration. Losartan potassium (Cozaar) label update: pregnancy teratogenicity. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020386s057lbl.pdf
- Epstein M, Reaven NL, Funk SE, et al. Assessment of the treatment gap between the clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212-220. https://pubmed.ncbi.nlm.nih.gov/26638948/
- American Diabetes Association. Microvascular complications and foot care: Standards of Medical Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S231-S243. https://diabetesjournals.org/care/article/47/Supplement_1/S231/153964
- Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. https://pubmed.ncbi.nlm.nih.gov/23299298/